Eliminatingde novo donor specific antibodies with immunoadsorption for improving platelet engraftment after allogeneic hematopoietic stem cell transplantation: one case report
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
万方数据
通过回顾2021年3月苏州大学附属第一医院收治的1例重型再生障碍性贫血患者，应用蛋白A免疫吸附（immunoadsorption，IA）技术清除造血干细胞移植后新生供体特异性抗体（donor specific antibody，DSA）促进血小板植入的诊疗过程，探讨IA技术清除单倍体造血干细胞移植后新生DSA的疗效和安全性。 To explore the efficacy and safety of immunoadsorption (IA) in removing de novo donor specific antibody (DSA) after allogeneic hematopoietic stem cell transplantation (HSCT), the relevant clinical data were retrospectively reviewed for one female patient of severe aplastic anemia (SAA). Desensitization treatment with IA after HSCT was offered for removing de novo DSA and ultimately promoting platelet engraftment at First Affiliated Hospital of Soochow University in March 2021.
To explore the efficacy and safety of immunoadsorption (IA) in removing de novo donor specific antibody (DSA) after allogeneic hematopoietic stem cell transplantation (HSCT), the relevant clinical data were retrospectively reviewed for one female patient of severe aplastic anemia (SAA). Desensitization treatment with IA after HSCT was offered for removing de novo DSA and ultimately promoting platelet engraftment at First Affiliated Hospital of Soochow University in March 2021.
Aplastic anemiaImmunoadsorptionHaploidentical hematopoietic stem cell transplantationDonor specific antibody
万方数据
